Galsky, Matthew D. http://orcid.org/0000-0001-7655-9378
Daneshmand, Siamak
Izadmehr, Sudeh http://orcid.org/0000-0001-8948-5689
Gonzalez-Kozlova, Edgar http://orcid.org/0000-0002-6948-0626
Chan, Kevin G. http://orcid.org/0000-0001-6041-1344
Lewis, Sara
Achkar, Bassam El
Dorff, Tanya B.
Cetnar, Jeremy Paul
Neil, Brock O.
D’Souza, Anishka
Mamtani, Ronac
Kyriakopoulos, Christos http://orcid.org/0000-0002-6452-7405
Jun, Tomi
Gogerly-Moragoda, Mahalya http://orcid.org/0000-0001-6982-2078
Brody, Rachel
Xie, Hui
Nie, Kai
Kelly, Geoffrey
Horowitz, Amir
Kinoshita, Yayoi
Ellis, Ethan
Nose, Yohei
Ioannou, Giorgio
Cabal, Rafael
Del Valle, Diane M.
Haines, G. Kenneth
Wang, Li
Mouw, Kent W.
Samstein, Robert M. http://orcid.org/0000-0001-6860-2401
Mehrazin, Reza
Bhardwaj, Nina http://orcid.org/0000-0003-1865-4187
Yu, Menggang
Zhao, Qianqian
Kim-Schulze, Seunghee
Sebra, Robert http://orcid.org/0000-0001-9267-2426
Zhu, Jun http://orcid.org/0000-0003-0834-8178
Gnjatic, Sacha http://orcid.org/0000-0001-5643-9520
Sfakianos, John
Pal, Sumanta K. http://orcid.org/0000-0002-1712-0848
Funding for this research was provided by:
V Foundation for Cancer Research (T2019-011)
Bristol-Myers Squibb (CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU, CA209-9AU)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA196521, U24CA224319)
Foundation for the National Institutes of Health (FNIH)/Partnership for Accelerating Cancer Therapies
Article History
Received: 10 January 2023
Accepted: 24 August 2023
First Online: 2 October 2023
Change Date: 19 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02814-0
Competing interests
: M.D.G. has received research funding from Bristol Myers Squibb, Novartis, Dendreon, AstraZeneca, Merck and Genentech. He has served as a consultant to Bristol Myers Squibb, Merck, Genentech, AstraZeneca, Pfizer, EMD Serono, SeaGen, Janssen, Numab, Dragonfly, GlaxoSmithKline, Basilea, UroGen, Rappta Therapeutics, Alligator, Silverback, Fujifilm, Curis, Gilead, Bicycle, Asieris, Abbvie and Analog Devices. S.D. has served as a consultant to Janssen, Ferring, Photocure, Taris, Pacific Edge, QED, Abbvie, Janssen, Bristol Myers Squibb, Sesen, Protara, Pfizer and CG Oncology. T.B.D. has served as a consultant to Astellas, AstraZeneca, Bayer, Janssen and Sanofi. R.M. has served as a consultant to Bristol Myers Squibb, Roche, Astellas and Seattle Genetics and has received research funding from Merck and Astellas. C.K. has served as a consultant to Exelixis, Sanofi, AVEO, EMD Serono and Janssen and has received research funding from Sanofi, Gilead Sciences, AstraZeneca, ESSA Pharma, Pionyr and Incyte. He owns stock in Biogen and Epic Systems. T.J. is an employee of Genentech. A.H. has served as a consultant to HTG Molecular Diagnostics and Immunorizon. L.W. is an employee of GeneDx. K.W.M. has served as a consultant to EMD Serono, Pfizer, UroGen and Riva Therapeutics, has received research support from Pfizer and Novo Ventures, has equity in Riva Therapeutics, has received writing fees from UpToDate and has received speaking fees from OncLive. He is named on an institutional patent filed on mutational signatures of DNA repair deficiency. N.B. has served as a consultant to Apricity, BreakBio, Carisma Therapeutics, CureVac, Genetech, Novartis, Primevax, Tempest Therapeutics, Dragonfly Therapeutics, BioNTech, Genotwin and Rome Therapeutics. She has received research support from Harbour Biomed Sciences and Regeneron. J.Z. is an employee of GeneDx. S.G. received research funding from Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Genentech, Regeneron and Takeda. J.S. has served as a consultant or advisor for Natera, Pacific Edge, Merck, Urogen and Janssen. S.K.P. has received travel support form CRISPR Therapeutics and Ipsen. All remaining authors declare no competing interests.